155 related articles for article (PubMed ID: 37775918)
21. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
[TBL] [Abstract][Full Text] [Related]
22. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
23. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
Hahn E; Chavira R; Wollenberg L; Tan W; Reddy MB
Clin Transl Sci; 2023 Dec; 16(12):2675-2686. PubMed ID: 37837178
[TBL] [Abstract][Full Text] [Related]
24. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
Al-Salama ZT
Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
26. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
[TBL] [Abstract][Full Text] [Related]
27. Pancreatitis After Treatment With Encorafenib, Binimetinib, and Cetuximab for BRAF V600E Mutation-Positive Colorectal Cancer.
Kureyama Y; Hanaoka Y; Tomita D; Matoba S; Kuroyanagi H
Cureus; 2024 May; 16(5):e60188. PubMed ID: 38741697
[TBL] [Abstract][Full Text] [Related]
28. Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF
Ji J; Wang C; Fakih M
Clin Colorectal Cancer; 2022 Sep; 21(3):267-271. PubMed ID: 35039233
[No Abstract] [Full Text] [Related]
29. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
Trullas A; Delgado J; Koenig J; Fuerstenau U; Dedorath J; Hausmann S; Stock T; Enzmann H; Pignatti F
ESMO Open; 2021 Feb; 6(1):100031. PubMed ID: 33422765
[TBL] [Abstract][Full Text] [Related]
30. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
31. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
[TBL] [Abstract][Full Text] [Related]
32. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract][Full Text] [Related]
33. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
34. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
[TBL] [Abstract][Full Text] [Related]
35. Encorafenib, binimetinib and cetuximab combined therapy for patients with
Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
[TBL] [Abstract][Full Text] [Related]
36. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
[TBL] [Abstract][Full Text] [Related]
37. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
38. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study.
Sakata H; Murase M; Kato T; Yamaguchi K; Sugihara K; Suzuki S; Yoshino T
Int J Clin Oncol; 2023 Jan; 28(1):139-144. PubMed ID: 36355316
[TBL] [Abstract][Full Text] [Related]
39. Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.
Okten IN; Ismail S; Withycombe BM; Eroglu Z
Expert Opin Drug Discov; 2020 Dec; 15(12):1373-1380. PubMed ID: 32720533
[TBL] [Abstract][Full Text] [Related]
40. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
Future Oncol; 2024 Feb; ():. PubMed ID: 38357801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
